Leukemia Research
Volume 34, Issue 10 , Pages 1296-1301 , October 2010

FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: Verification of the method and application to 27 MDS patients

  • Friederike Braulke

      Affiliations

    • Department of Hematology and Oncology, Georg-August University, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • ,
  • Julie Schanz

      Affiliations

    • Department of Hematology and Oncology, Georg-August University, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • ,
  • Klaus Jung

      Affiliations

    • Department of Medical Statistics, Georg-August University, Goettingen, Germany
    • ,
  • Katayoon Shirneshan

      Affiliations

    • Department of Hematology and Oncology, Georg-August University, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • ,
  • Kristina Schulte

      Affiliations

    • Department of Hematology and Oncology, Georg-August University, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • ,
  • Claudia Schuetze

      Affiliations

    • Department of Hematology and Oncology, Georg-August University, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • ,
  • Rainer Steffens

      Affiliations

    • Department of Hematology and Oncology, Georg-August University, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • ,
  • Lorenz Trümper

      Affiliations

    • Department of Hematology and Oncology, Georg-August University, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • ,
  • Detlef Haase

      Affiliations

    • Department of Hematology and Oncology, Georg-August University, Robert-Koch-Str. 40, 37075 Goettingen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 551 39 6313; fax: +49 551 39 12534.

Received 3 November 2009 ,Revised 7 January 2010 ,Accepted 9 January 2010.

References 

  1. Silverman LR. Neoplasms of the hematopoietic system: myelodysplastic syndrome. In:  Holland J,  Frei EI,  Bast RJ editor. Cancer medicine. Hamilton, Canada: BC decker; 2000;p. 1931–1946
  2. Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Seminars in hematology. 2004;41(Suppl. 4 (2)):6–12
  3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplstic syndromes. Blood. 1997;89(6):2079–2088
  4. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leukemia Research. 2000;24:983–992
  5. Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, et al. Incidence, characterisation and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. British Journal of Haematology. 2000;108(2):346–356
  6. Giagounidis AAN, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. Prognosis of patients with del(5q) MDS and complex aberrant karyotype and the possible role of lenalidomide in this patient subgroup. Annals of Hematology. 2005;84:569–571
  7. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. New England Journal of Medicine. 2005;352(6):549–557
  8. Raj KK, John AM, Ho A, Thomas NSB, Mufti GJ. Early and sustained response to Azacytidine in high-risk MDS patients with monosomy 7 correlates with increased apoptosis and not CDKN2B demethylation [abstract 2530]. Blood. 2005;106:710a
  9. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into prgnostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385–4395
  10. Haase D, Fonatsch C, Freund M, Wörmann B, Bodenstein H, Bartels H, et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Annals of Hematology. 1995;70(4):171–187
  11. Bernasconi P, Klersy C, Boni M, Cavigliano PM, Calatroni S, Giardini I, et al. Incidence and prognostic significance of karyotype abnormalities in de novo myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia. 2005;19(8):1424–1431
  12. Rigolin GM, Bigoni R, Milani R, Cavazzini F, Roberti MG, Bardi A, et al. Clinical imprtance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia. 2001;15(12):1841–1847
  13. Vehmeyer K, Haase D, Alves F. Increased peripheral stem cell pool in MDS: an indication of disease progression?. Leukemia Research. 2001;25(11):955–959
  14. Haase D, Feuring-Buske M, Könemann S, Fonatsch C, Troff C, Verbeek W, et al. Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood. 1995;86(8):2906–2912
  15. Haase D, Feuring-Buske M, Schäfer C, Schoch C, Troff C, Gahn B, et al. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia. 1997;11(5):674–679
  16. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology. 1999;17(12):3835–3849
  17. Mitelman F. An international system for human cytogenetic nomenclature. Recommendations of the International Standing Committee on human cytogenetic nomenclature. Memphis. Basel: S. Karger A.G.; 1995;
  18. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425
  19. Christman J, Mendelsohn N, Herzog D, Schneiderman N. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Research. 1983;43:763–769
  20. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacytidine compared with that of conventional care regimens in treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology. 2009;10(3):223–232
  21. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, et al. Cytogenetic response in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. British Journal of Haematology. 2001;114(2):349–357
  22. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacytidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. Journal of Clinical Oncology. 2002;20(10):2429–2440
  23. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Journal of Clinical Oncology. 2006;24(24):3895–3903
  24. Silverman LR, Mufti GJ. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nature Clinical Practice. 2005;2(1):1–12
  25. Sullivan M, Hahn K, Kolesar JM. Azacytidine: a novel agent for myelodysplastic syndromes. American Journal of Health-System Pharmacy. 2005;62(15):1567–1573
  26. Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimes (CCR): results of the AZA-001 phase III study [abstract]. Blood. 2007;110:817;[ASH Annual Meeting Abstracts]
  27. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hyperinterphase-FISH, qualitative and quantitativ PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16:53–59
  28. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommandations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820

PII: S0145-2126(10)00011-1

doi: 10.1016/j.leukres.2010.01.010

Leukemia Research
Volume 34, Issue 10 , Pages 1296-1301 , October 2010

Article Tools

* Image Usage & Resolution